anti cd123 monoclonal antibody khk2823

Drug Overview

The medication known as anti cd123 monoclonal antibody khk2823 is an investigational, humanized monoclonal antibody designed to treat aggressive blood cancers, specifically Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). It targets the “building blocks” of cancer by focusing on CD123, the alpha chain of the interleukin-3 receptor ($IL-3R\alpha$).

Developed by Kyowa Kirin, KHK2823 is engineered using advanced Potelligent® technology. This specific process removes a sugar molecule (fucose) from the antibody, which significantly boosts its ability to recruit the body’s natural killer (NK) cells. Its primary mission is to identify and destroy Leukemic Stem Cells (LSCs)—the resilient “seeds” of leukemia that often survive standard chemotherapy and cause the cancer to return.

• Generic Name: KHK2823.
• Drug Class: Humanized Monoclonal Antibody (IgG1).
• Target: CD123 (IL-3 receptor alpha).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Investigational. As of March 2026, KHK2823 is not FDA-approved. It has completed Phase I clinical trials, and researchers are evaluating its safety and preliminary activity as a foundation for more complex, targeted leukemia therapies.

What Is It and How Does It Work? (Mechanism of Action)

The CD123 Target

CD123 is a protein found on the surface of many hematological malignancies. It is highly overexpressed on AML blasts and Leukemic Stem Cells (LSCs) but has very low expression on healthy blood-forming stem cells. This makes it an ideal “biological target” for precision therapy.

Molecular Level Mechanisms

1. High-Affinity Binding: Once infused, KHK2823 circulates and locks onto the CD123 protein on the surface of leukemia cells.
2. Fc-Engineered Recruitment: Because KHK2823 is “non-fucosylated” (using Potelligent® technology), its tail end (the Fc region) binds much more strongly to the receptors on Natural Killer (NK) cells.
3. Immune-Mediated Destruction: The NK cells recognize the “flagged” cancer cell and release toxic proteins (perforins and granzymes) that poke holes in the leukemia cell, causing it to burst and die (lysis).
4. Inhibition of IL-3 Signaling: By coating the CD123 receptor, the drug may also block the binding of the natural growth factor IL-3, effectively starving the cancer cell of signals it needs to multiply.
5. Selective Stem Cell Targeting: Unlike broad chemotherapy, KHK2823 is designed to find the rare, dormant stem cells that drive the disease, potentially leading to more durable remissions.

FDA Approved Clinical Indications

There are currently no FDA-approved clinical indications for KHK2823.

It has been primarily investigated in the following settings through clinical trials (such as NCT02181699):

• Relapsed or Refractory Acute Myeloid Leukemia (AML): For adult patients who have failed at least one prior line of therapy.
• Relapsed or Refractory Myelodysplastic Syndromes (MDS): Specifically for patients who have not responded to hypomethylating agents (like Azacitidine).
• Untreated AML in Ineligible Patients: For elderly patients or those who are not candidates for intensive induction chemotherapy.

Dosage and Administration Protocols

Because KHK2823 is an investigational agent, there is no established “Standard of Care” dose. The following were the protocols established during its Phase I first-in-human study.

Clinical Efficacy and Research Results

The clinical data from Phase I studies (updated through 2024–2026) has defined KHK2823’s role in the leukemia pipeline.

• Target Saturation: Researchers confirmed that KHK2823 successfully binds to CD123+ cells in the blood and bone marrow at very low doses, indicating high biological potency.
• Antitumor Activity: In the dose-escalation cohorts, several patients experienced a significant reduction in bone marrow “blast” counts. While complete remissions were rare as a single agent, the drug showed a strong ability to stabilize the disease in heavily pre-treated patients.
• Safety Milestones: KHK2823 demonstrated a more favorable safety profile than many of its predecessors (like the bispecific antibodies), showing that “naked” antibodies may be a safer way to target CD123 without overwhelming the immune system.

Safety Profile and Side Effects

As an immunotherapy, KHK2823 is generally better tolerated than traditional chemotherapy, though it carries risks related to its immune-stimulating properties.

Common Side Effects (>15%):

• Infusion-Related Reactions (IRRs): Fever, chills, and flushing during the infusion. This is usually managed with pre-medication.
• Fatigue: A general sense of tiredness following treatment.
• Nausea: Usually mild and manageable with standard anti-emetics.
• Pyrexia: Temporary fever in the 24 hours following the dose.

Serious Adverse Events:

• Myelosuppression: A drop in blood cell counts (neutropenia or thrombocytopenia), which is expected when targeting cells in the bone marrow.
• Infections: Increased risk of infection due to low white blood cell counts.
• Capillary Leak Syndrome (CLS): Though rare with this specific antibody, it is a known risk for CD123-targeting agents and requires monitoring for sudden swelling or low blood pressure.

Research Areas

In the field of Stem Cell and Regenerative Medicine, KHK2823 is a cornerstone for studying “Hematopoietic Niche Protection.” CD123 is a marker that differentiates “evil” leukemia stem cells from “good” healthy blood stem cells. Researchers are using KHK2823 to study how to “clear the niche” of cancer before a patient undergoes a Stem Cell Transplant. This ensures that the transplanted healthy cells have a clean environment to grow, potentially improving the success rate of transplants in high-risk leukemia patients.

Patient Management and Practical Recommendations

Pre-treatment Tests:

• CD123 Expression Baseline: A flow cytometry test on bone marrow or blood is required to ensure the cancer expresses the target.
• Baseline CBC with Differential: To track immune cell levels throughout the cycle.
• Liver and Kidney Function: Standard panels to ensure the patient can process the medication.

Precautions:

• Pre-medication: Patients are typically given acetaminophen and an antihistamine (like Diphenhydramine) 30–60 minutes before the infusion to prevent reactions.
• Infection Monitoring: Report any fever over 100.4°F (38°C) immediately.

“Do’s and Don’ts” List:

• DO report any “shaking chills” or itching during the infusion to your nurse immediately.
• DO keep a diary of your energy levels, as fatigue can be cumulative over several cycles.
• DON’T ignore sudden swelling in your ankles or face, as this can be an early sign of fluid issues.
• DON’T skip follow-up blood work; monitoring your platelets and white cells is the “safety net” of this therapy.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. KHK2823 is an investigational agent and is not currently approved by the US Food and Drug Administration (FDA) for any condition. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding currently available and approved treatments or your eligibility for research studies.